0.00Open0.10Pre Close0 Volume10 Open Interest12.50Strike Price0.00Turnover153.99%IV31.64%PremiumNov 15, 2024Expiry Date0.00Intrinsic Value100Multiplier9DDays to Expiry0.10Extrinsic Value100Contract SizeAmericanOptions Type-0.0493Delta0.0231Gamma181.40Leverage Ratio-0.0236Theta-0.0002Rho-8.95Eff Leverage0.0029Vega
Kura Oncology Stock Discussion
Kura Oncology Announces Publication of Ziftomenib Phase 1 Results in The Lancet Oncology | KURA Stock News
$Kura Oncology (KURA.US)$
No comment yet